Document:

exv4w4

 

Exhibit 4.4

POLYMEDIX, INC.

WARRANT TO PURCHASE COMMON STOCK

To Purchase [ ] Shares of Common Stock

Date of Issuance:                     , 2007

VOID AFTER [     ], 2012

     THIS CERTIFIES THAT, for value received, [                    ], or permitted registered assigns (the
“Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from
Polymedix, Inc., a Delaware corporation (the “Company”), up to [                    ] shares of the common
stock of the Company, par value $0.001 per share (the “Common Stock”). This warrant is one of a
series of warrants issued by the Company as of the date hereof (individually a “Warrant”,
collectively, “Company Warrants”) pursuant to that certain subscription agreement between the
Company and the Holder, dated as of                     , 2007 (the “Subscription Agreement”).

     1. DEFINITIONS. Capitalized terms used herein but not otherwise defined herein shall
have their respective meanings as set forth in the Subscription Agreement. As used herein, the
following terms shall have the following respective meanings:

          (a) “Exercise Period” shall mean the period commencing with the date occurring six months
after the date hereof and ending five years from the date hereof, unless sooner terminated as
provided below.

          (b) “Exercise Price” shall mean $                     per share, subject to adjustment pursuant to
Section 4 below.

          (c) “Exercise Shares” shall mean the shares of Common Stock issuable upon exercise of this
Warrant.

          (d) “Trading Day” shall mean (i) any day on which the Common Stock is listed or quoted and
traded on its primary Trading Market, (ii) if the Common Stock is not then listed or quoted and
traded on any eligible market (meaning any of the New York Stock Exchange, American Stock Exchange
(“AMEX”) or The NASDAQ Global Market), then a day on which trading occurs on the OTC Bulletin Board
(or any successor thereto), or (iii) if trading does not occur on the OTC Bulletin Board (or any
successor thereto), any business day.

     2. EXERCISE OF WARRANT. The rights represented by this Warrant may be, subject to
Section 6 below, exercised in whole or in part at any time during the Exercise Period, by delivery
of the following to the Company at its address set forth on the signature page hereto (or at such
other address as it may designate by notice in writing to the Holder):

          (a) An executed Notice of Exercise in the form attached hereto; and

          (b) Payment of the Exercise Price either in cash or by check.

 

 

     Execution and delivery of the Notice of Exercise shall have the same effect as cancellation of
the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining
number of Exercise Shares, if any. If requested by the Company, Holder agrees to provide this
Warrant, or an affidavit of lost security, to the Company within a reasonable period after the
delivery of the Notice of Exercise.

     Certificates for shares purchased hereunder shall be transmitted by the transfer agent of the
Company to the Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company through its Deposits and Withdrawal at Custodian (DWAC) system if the Company is a
participant in such system, and otherwise by physical delivery to the address specified by the
Holder in the Notice of Exercise within three business days from the delivery to the Company of the
Notice of Exercise, surrender of this Warrant and payment of the aggregate Exercise Price as set
forth above. This Warrant shall be deemed to have been exercised on the date the Exercise Price is
received by the Company. The Exercise Shares shall be deemed to have been issued, and Holder or
any other person so designated to be named therein shall be deemed to have become a holder of
record of such shares for all purposes, as of the date this Warrant has been exercised by payment
to the Company of the Exercise Price. If by the close of the third Trading Day after delivery of a
Notice of Exercise, the Company fails to deliver to the Holder a certificate representing the
required number of Exercise Shares in the manner required pursuant to this Section 2, and
such failure to deliver the Exercise Shares is caused by the Company’s failure to use commercially
reasonable efforts to comply with this Section 2 and/or the covenants in Section
3.1 herein, and if after such third Trading Day and prior to the receipt of such Exercise
Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to
deliver in satisfaction of a sale by the Holder of the Exercise Shares which the Holder anticipated
receiving upon such exercise (a “Buy-In”), then the Company shall, within three Trading Days after
the Holder’s request and in the Holder’s sole discretion, either (1) pay in cash to the Holder an
amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the
shares of Common Stock so purchased (the “Buy-In Price”), at which point the Company’s obligation
to deliver such certificate (and to issue such Exercise Shares) shall terminate or (ii) promptly
honor its obligation to deliver to the Holder a certificate or certificates representing such
Exercise Shares and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In
Price over the product of (a) such number of Exercise Shares, times (b) the closing bid price on
the date of the event giving rise to the Company’s obligation to deliver such certificate.

     The person in whose name any Exercise Shares are to be issued upon exercise of this Warrant
shall be deemed to have become the holder of record of such shares on the date on which this
Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of
delivery of such certificate or certificates, except that, if the date of such surrender and
payment is a date when the stock transfer books of the Company are closed, such person shall be
deemed to have become the holder of such shares at the close of business on the next succeeding
date on which the stock transfer books are open.

     To the extent permitted by law, the Company’s obligations to issue and deliver Exercise Shares
in accordance with the terms hereof are absolute and unconditional, irrespective of any action or
inaction by the Holder to enforce the same, any waiver or consent with respect to any provision
hereof, the recovery of any judgment against any person or entity or any action to

2

 

enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any
breach or alleged breach by the Holder or any other person or entity of any obligation to the
Company or any violation or alleged violation of law by the Holder or any other person or entity,
and irrespective of any other circumstance which might otherwise limit such obligation of the
Company to the Holder in connection with the issuance of Exercise Shares. Nothing herein shall
limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with
respect to the Company’s failure to timely deliver certificates representing shares of Common Stock
upon exercise of this Warrant as required pursuant to the terms hereof.

          2.2 ISSUANCE OF NEW WARRANTS. Upon any partial exercise of this Warrant, the Company,
at its expense, will forthwith and, in any event within five business days, issue and deliver to
the Holder a new warrant or warrants of like tenor, registered in the name of the Holder,
exercisable, in the aggregate, for the balance of the number of shares of Common Stock remaining
available for purchase under this Warrant.

          2.3 EXERCISE LIMITATIONS; HOLDER’S RESTRICTIONS. A Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent
that after giving effect to such issuance after exercise, such Holder (together with such Holder’s
affiliates), as set forth on the applicable Notice of Exercise, would beneficially own in excess of
4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
such issuance. For purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by such Holder and its affiliates shall include the number of shares of Common
Stock issuable upon exercise of this Warrant with respect to which the determination of such
sentence is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (a) exercise of the remaining, non-exercised portion of this Warrant beneficially
owned by such Holder or any of its affiliates and (b) exercise or conversion of the unexercised or
non-converted portion of any other securities of the Company (including, without limitation, any
other shares of Common Stock or Warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by such Holder or any of its
affiliates. Except as set forth in the preceding sentence, for purposes of this Section
2.3, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act, it being acknowledged by a Holder that the Company is not representing to such Holder that
such calculation is in compliance with Section 13(d) of the Exchange Act and such Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the
limitation contained in this Section 2.3 applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by such Holder) and of which a portion of
this Warrant is exercisable shall be in the sole discretion of a Holder, and the submission of a
Notice of Exercise shall be deemed to be each Holder’s determination of whether this Warrant is
exercisable (in relation to other securities owned by such Holder) and of which portion of this
Warrant is exercisable, in each case subject to such aggregate percentage limitation, and the
Company shall have no obligation to verify or confirm the accuracy of such determination. For
purposes of this Section 2.3, in determining the number of outstanding shares of Common
Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)
the Company’s most recent Form 10-Q or Form 10-K, as the case may be, (y) a more recent public
announcement by the Company or (z) any other notice by the Company or the Company’s Transfer Agent
setting forth the number of shares of

3

 

Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall
within two Trading Days confirm orally and in writing to such Holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by such Holder or its affiliates since the date as of which such number of
outstanding shares of Common Stock was reported. The provisions of this Section 2.3 may be
waived by such Holder, at the election of such Holder, upon not less than 61 days’ prior notice to
the Company, and the provisions of this Section 2.3 shall continue to apply until such 61st
day (or such later date, as determined by such Holder, as may be specified in such notice of
waiver).

     3. COVENANTS OF THE COMPANY.

          3.1 COVENANTS AS TO EXERCISE SHARES. The Company covenants and agrees that all
Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant
will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from
all taxes, liens and charges with respect to the issuance thereof. The Company further covenants
and agrees that the Company will at all times during the Exercise Period, have authorized and
reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for
the exercise of the rights represented by this Warrant. If at any time during the Exercise Period
the number of authorized but unissued shares of Common Stock shall not be sufficient to permit
exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its
counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number
of shares as shall be sufficient for such purposes. The Company shall use commercially reasonable
efforts to keep a registration statement (a “Registration Statement”) with respect to the issuance
and sale of the Exercise Shares to the Holder, or such Holder’s valid assignee, in effect during
the Exercise Period or such shorter period that will terminate when this Warrant has been
exercised, and during such time period shall use commercially reasonable efforts to obtain the
prompt withdrawal of any stop order suspending the effectiveness of any such Registration
Statement. At any time during which the Exercise Shares are included in a then-effective
Registration Statement, the Company may suspend the ability of the Holder to exercise this Warrant
in any manner contemplated by this Warrant, for a reasonable period or periods (a “Black-out
Period”), in the event that (i)(a) an event occurs and is continuing as a result of which the
Registration Statement including the Exercise Shares, any related prospectus or any document
incorporated therein by reference as then amended or supplement would, in the Company’s good faith
judgment, contain an untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading, and (b) the Company determined in its good faith judgment that the disclosure
of such event at such time would be to the detriment of the business, operations or prospects of
the Company or the disclosure otherwise relates to a business transaction, operations or other
material event which has not yet been publicly disclosed, or (ii) the Registration Statement is no
longer effective and the holder is not permitted to sell Exercise Shares pursuant to any other
registration statement or an exemption to the registration requirements of the Securities Act of
1933, as amended (the “Securities Act”); provided, however, that in the event that a Black-out
Period occurs subsequent to the one year anniversary of the Date of Issuance, this Warrant shall be
exercised subject to the terms and conditions of Section 2.1.

4

 

Notwithstanding the foregoing provisions of this Section 3.1, (i) if a Holder is not
able to exercise this Warrant because the Company has implemented a Black-out Period, then the
Exercise Period shall be extended for the number of calendar days covered by such Black-out Period
and (ii) the Company will use commercially reasonable efforts to ensure that the aggregate number
of days covered by Black-out Periods shall not last for more than twenty (20) consecutive days or
exceed sixty (60) in a particular calendar year; provided, however, that the holder may not receive
any penalties, cash payments or any other liquidated damages for failure to deliver registered
Exercise Shares so long as the Company has used commercially reasonable efforts to deliver the
Holder the Exercise Shares as contemplated in Section 2 herein or otherwise complies with the
covenants in this Section 3.1, and (c) if the Black-out Period is required because the
Registration Statement is no longer effective and the Holder is not permitted to sell Exercise
Shares pursuant to any other registration statement or an exemption to the registration
requirements of the Securities Act of 1933, then the Exercise Period shall be extended until such
Holder may sell such Exercise Shares.

          3.2 NO IMPAIRMENT. Except and to the extent as waived or consented to by the holders
of Company Warrants representing at least two-thirds of the number of shares of Common Stock then
subject to outstanding Company Warrants, the Company will not, by amendment of its Certificate of
Incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms to be observed or performed hereunder by the Company,
but will at all times in good faith assist in the carrying out of all the provisions of this
Warrant and in the taking of all such action as may be necessary or appropriate in order to protect
the exercise rights of the Holder against impairment.

     4. ADJUSTMENT OF EXERCISE PRICE AND SHARES.

          (a) In the event of changes in the outstanding Common Stock of the Company by reason of stock
dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares,
separations, reorganizations, liquidations, consolidation, acquisition of the Company (whether
through merger or acquisition of substantially all the assets or stock of the Company), or the
like, the number, class and type of shares available under this Warrant in the aggregate and the
Exercise Price shall be correspondingly adjusted to give the Holder of this Warrant, on exercise
for the same aggregate Exercise Price, the total number, class, and type of shares or other
property as the Holder would have owned had this Warrant been exercised prior to the event and had
the Holder continued to hold such shares until the event requiring adjustment. The form of this
Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to
this Warrant.

          (b) If at any time or from time to time the holders of Common Stock of the Company (or any
shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall
have received or become entitled to receive, without payment therefor,

               (i) Common Stock or any shares of stock or other securities which are at any time
directly or indirectly convertible into or exchangeable for Common Stock, or any rights or
options to subscribe for, purchase or otherwise acquire any of the foregoing

5

 

by way of dividend or other distribution (other than a dividend or distribution covered
in Section 4(a) above);

                (ii) any cash paid or payable otherwise than as a cash dividend; or

                (iii) Common Stock or additional stock or other securities or property (including cash)
by way of spinoff, split-up, reclassification, combination of shares or similar corporate
rearrangement (other than shares of Common Stock pursuant to Section 4(a) above),

then and in each such case, the Holder hereof will, upon the exercise of this Warrant, be entitled
to receive, in addition to the number of shares of Common Stock receivable thereupon, and without
payment of any additional consideration therefor, the amount of stock and other securities and
property, as applicable, (including cash in the cases referred to in clauses (ii) and (iii) above)
which such Holder would hold on the date of such exercise had such Holder been the holder of record
of such Common Stock as of the date on which holders of Common Stock received or became entitled to
receive such shares or all other additional stock and other securities and property.

          (c) Upon the occurrence of each adjustment pursuant to this Section 4, the Company at
its expense will, at the written request of the Holder, promptly compute such adjustment in
accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment,
including a statement of the adjusted Exercise Price and adjusted number or type of Exercise Shares
or other securities issuable upon exercise of this Warrant (as applicable), describing the
transactions giving rise to such adjustments and showing in detail the facts upon which such
adjustment is based. Upon written request, the Company will promptly deliver a copy of each such
certificate to the Holder and to the Company’s transfer agent.

     5. FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise of this
Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including
fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
whether the exercise would result in the issuance of any fractional share. If, after aggregation,
the exercise would result in the issuance of a fractional share, the Company shall, in lieu of
issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash
equal to the product resulting from multiplying the then current Fair Market Value of an Exercise
Share by such fraction. “Fair Market Value” of one share of Common Stock shall mean (i) the
average of the closing sales prices for the shares of Common Stock on AMEX or other trading market
where such security is listed or traded as reported by Bloomberg Financial Markets (or a comparable
reporting service of national reputation selected by the Company and reasonably acceptable to the
Holder if Bloomberg Financial Markets is not then reporting sales prices of such security)
(collectively, “Bloomberg”) for the ten (10) consecutive trading days immediately preceding such
date, or (ii) if AMEX is not the principal trading market for the shares of Common Stock, the
average of the reported sales prices reported by Bloomberg on the principal trading market for the
Common Stock during the same period, or, if there is no sales price for such period, the last sales
price reported by Bloomberg for such period, or (iii) if neither of the foregoing applies, the last
sales price of such security in the over-the-counter market on the pink sheets or bulletin board
for such security as reported by Bloomberg, or if no sales price

6

 

is so reported for such security, the last bid price of such security as reported by Bloomberg
or (iv) if Fair Market Value cannot be calculated as of such date on any of the foregoing bases,
the Fair Market Value shall be as determined by the Board of Directors of the Company in the
exercise of its good faith judgment.

     6. FUNDAMENTAL TRANSACTIONS. If, at any time while this Warrant is outstanding, (i)
the Company effects any merger or consolidation of the Company with or into another entity, in
which the shareholders of the Company as of immediately prior to the transaction own less than a
majority of the outstanding stock of the surviving entity, (ii) the Company effects any sale of all
or substantially all of its assets in one or a series of related transactions, (iii) any tender
offer or exchange offer (whether by the Company or another person or entity) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their shares for other
securities, cash or property, or (iv) the Company effects any reclassification of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property (other than as a result of a subdivision or
combination of shares of Common Stock covered by Section 4 above) (each, a “Fundamental
Transaction”), then the Holder shall have the right thereafter to receive, upon exercise of this
Warrant, the same amount and kind of securities, cash or property, as applicable, as it would have
been entitled to receive upon the occurrence of such Fundamental Transaction if it had been,
immediately prior to such Fundamental Transaction, the holder of the number of Exercise Shares then
issuable upon exercise in full of this Warrant (the “Alternate Consideration”). Following any
transaction contemplated by this Section 6, the term Exercise Shares shall be deemed to
refer to the shares for which this Warrant is thereafter exercisable in accordance with the
provisions hereof. In addition, if holders of Common Stock are given a choice as to the securities,
cash (which shall be treated in accordance with the preceding paragraph) or property to be received
in a Fundamental Transaction (including a right to elect to receive any particular one or
combination of more than one of the foregoing), then the Holder shall be given the same choice of
consideration upon any exercise of this Warrant following such Fundamental Transaction, which
choice of consideration can be made at the time of exercise at any time prior to the expiration of
the Exercise Period.

     7. NO STOCKHOLDER RIGHTS. Other than as provided in Section 3.3 or otherwise
herein, this Warrant in and of itself shall not entitle the Holder to any voting rights or other
rights as a stockholder of the Company.

     8. TRANSFER OF WARRANT. Subject to compliance with any applicable laws, this Warrant
and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney,
upon delivery of this Warrant and the form of assignment attached hereto to any transferee
designated by the Holder. The transferee shall sign an investment letter in form and substance
reasonably satisfactory to the Company and its counsel.

     9. LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen,
mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may
reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or
destroyed. Any such new Warrant shall constitute an original

7

 

contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or
destroyed Warrant shall be at any time enforceable by anyone.

     10. NOTICES, ETC. All notices required or permitted hereunder shall be in writing and
shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b)
when sent by confirmed telex, electronic transmission or facsimile if sent during normal business
hours of the recipient, if not, then on the next business day, (c) five days after having been sent
by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after
deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at the address listed on
the signature page hereto and to the Holder at the applicable address set forth on the applicable
signature page to the Subscription Agreement or at such other address as the Company or the Holder
may designate by ten (10) days advance written notice to the other parties hereto.

     11. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of
and agreement to all of the terms and conditions contained herein.

     12. GOVERNING LAW. This Warrant shall be governed by, and construed in accordance
with, the laws of the State of New York. The Holder hereby submits to the non-exclusive
jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of New York in
any suit or proceeding arising out of or relating to this Agreement or the transactions
contemplated thereby. The Holder irrevocably and unconditionally waives any objection to the
laying of venue of any suit or proceeding arising out of or relating to this Warrant in Federal and
state courts in the Borough of Manhattan in The City of New York and irrevocably and
unconditionally waives and agrees not to plead or claim in any such court that any such suit or
proceeding in any such court has been brought in an inconvenient forum.

     13. AMENDMENT OR WAIVER. Any term of this Warrant may be amended or waived (either generally
or in a particular instance and either retroactively or prospectively) with the written consent of
the Company and the holders of Company Warrants representing at least a two-thirds of the number of
shares of Common Stock then subject to outstanding Company Warrants. Notwithstanding the
foregoing, (a) this Warrant may be amended and the observance of any term hereunder may be waived
without the written consent of the Holder only in a manner which applies to all Company Warrants in
the same fashion and (b) the number of Exercise Shares subject to this Warrant and the Exercise
Price of this Warrant may not be amended, and the right to exercise this Warrant may not be waived,
without the written consent of the Holder. The Company shall give prompt written notice to the
Holder of any amendment hereof or waiver hereunder that was effected without the Holder’s written
consent. No waivers of any term, condition or provision of this Warrant, in any one or more
instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term,
condition or provision.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

8

 

     IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly authorized
officer as of ___, 2007.

	 	 	 	 	 
	 	 	POLYMEDIX, INC.
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	 	 	Name:
	 

	 	 	 	Title:
	 
	 	 	 	 
	 	 	170 N. Radnor-Chester Road
	 	 	Suite 300
	 	 	Radnor, Pennsylvania 19087

9

 

NOTICE OF EXERCISE

TO: POLYMEDIX, INC.

     (1) The undersigned hereby elects to purchase [                    ] shares of the common stock, par
value $0.001 (the “Common Stock”), of POLYMEDIX, INC. (the “Company”) pursuant to the terms of the
attached Warrant, and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any, subject to the limitations set forth in Section 2.1 of
the Warrant.

     (2) Please issue the certificate for shares of Common Stock in the name of, and pay any cash
for any fractional share to:

	 	 	 	 	 
	 
	 	 

Print or type name
	 	 
	 	 	 	 	 
	 
	 	 	 	 
	 
	 	Social Security or other Identifying Number	 	 
	 	 	 	 	 
	 
	 	 	 	 
	 
	 	Street Address	 	 
	 	 	 	 	 
	 
	 	 	 	 
	 
	 	City, State, Zip Code	 	 

     (3) If such number of shares shall not be all the shares purchasable upon the exercise of the
Warrants evidenced by this Warrant, a new warrant certificate for the balance of such Warrants
remaining unexercised shall be registered in the name of and delivered to:

     Please insert Social Security or other identifying number:                     

(Please print name and address)

	 	 	 	 	 	 	 
	Dated:
	 	 	 	 	 	 
	 

	 	 
	 	 	 	 
	 

	 	(Date)
	 	 	 	(Signature)
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	 	 	(Print Name)

10

 

ASSIGNMENT FORM

     (To assign the foregoing Warrant, execute this form and supply required information. Do not
use this form to purchase shares.)

     FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

	 	 	 	 	 
	 	 	 
	Name:
	 	(Please Print)
	 
	 	 	 	 
	 	 	 
	Address:
	 	(Please Print)
	 
	 	 	 	 
	Dated:

	 	 	 	, 2007
	 

	 	 	 	 
	 
	 	 	 	 
	Holder’s Signature:
	 	 	 	 
	 	 	 
	 
	 	 	 	 
	Holder’s Address:
	 	 	 	 
	 	 	 

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatever. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.

11exv10w20

 

Exhibit 10.20

                     Units

POLYMEDIX, INC.

PLACEMENT AGENCY AGREEMENT

July ___, 2007

Needham & Company, LLC

445 Park Avenue

New York, NY 10022

WBB Securities, LLC

16835 West Bernardo Drive

Suite 203

San Diego, CA 92127

Ladies and Gentlemen:

1. Introductory. Polymedix, Inc., a Delaware corporation (the “Company”), proposes, pursuant to
the terms of this Placement Agency Agreement (this “Agreement”) and the Subscription Agreements in
the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with
the purchasers identified therein (each a “Purchaser” and collectively, the “Purchasers”), to sell
to the Purchasers an aggregate of                      units (the “Units”) with each Unit consisting of (i)
___ shares (each, a “Share,” collectively, the “Shares”) of common stock, par value $0.001 per
share (the “Common Stock”) of the Company and (ii) one
warrant to purchase ___ shares of Common
Stock (each, a “Warrant,” collectively, the “Warrants”). The terms and conditions of the Warrants
are set forth in Exhibit B attached hereto. The Company hereby confirms its agreement with
Needham & Company, LLC (“Needham”) to act as lead placement agent and WBB Securities, LLC (“WBB
Securities”) to act as co-placement agent (Needham and WBB Securities, the “Placement Agents” and
each, a “Placement Agent”) in accordance with the terms and conditions hereof as set forth below.

2. Agreement to Act as Placement Agents; Placement of Units. On the basis of the representations,
warranties and agreements of the Company herein contained, and subject to all the terms and
conditions of this Agreement:

          (a) The Company engages the Placement Agents to act as its exclusive agents, on a best efforts
basis, in connection with the issuance and sale by the Company of the Units (the “Offering”). Until
the Closing Date (defined below), the Company shall not, without the prior consent of Needham,
solicit or accept offers to purchase Units otherwise than through the Placement Agents.

          (b) Under no circumstances will the Placement Agents be obligated to purchase any Units for
their own account and, in soliciting purchases of Units, the Placement Agents shall act solely as
the Company’s agents and not as principals. Notwithstanding the foregoing and except as otherwise
provided in Section 2(c), it is understood and agreed that the Placement Agents (or their
affiliates) may, solely at their discretion and without any obligation to do so, purchase Units as
principals to the extent any such purchase of Units is properly disclosed in the General Disclosure
Package in the manner required by the Securities Laws.

          (c) Subject to the provisions of this Section 2, offers for the purchase of Units may be
solicited by the Placement Agents as agents for the Company at such times and in such amounts as
the Placement Agents deem advisable. The Placement Agents shall communicate to the Company, orally
or in writing, each reasonable offer to purchase Units received by them as agents of the Company.
The Company shall have the sole right to accept offers to purchase the Units and may reject any
such offer, in whole or in part. The Placement Agents shall have the right, in their discretion
reasonably exercised, and subject to the consent of the Company not to be unreasonably withheld, to
reject any offer to purchase Units received by it, in whole or in part, and any such rejection
shall not be deemed a breach of its agreement contained herein.

          (d) The Units are being sold to the Purchasers at a price of $           per Unit. The purchases of
the Units by the Purchasers shall be evidenced by the execution of Subscription Agreements by each
of the parties thereto.

- 1 -

 

          (e) As compensation for services rendered, on the Closing Date, the Company shall pay to the
Placement Agents, which payment may be from the Escrow Funds (defined below), by wire transfer of
immediately available funds to an account or accounts designated by the Placement Agents, an
aggregate amount equal to seven percent (7%) of the gross proceeds (the “Placement Agent Fee”)
received by the Company from the sale of the Units on such Closing Date. At the Closing, the
Company and Needham shall direct the Escrow Agent to wire to an account or accounts designated by
the Placement Agents the Placement Agent Fee and the Placement Agent Expenses (defined below) out
of the Escrow Funds (defined below).

          (f) No Units which the Company has agreed to sell pursuant to this Agreement shall be deemed
to have been purchased and paid for, or sold by the Company, until such Units shall have been
delivered to the Purchaser thereof against payment by such Purchaser. If the Company shall default
in its obligations to deliver Units to a Purchaser whose offer it has accepted, the Company shall
indemnify and hold the Placement Agents harmless against any loss, claim or damage arising from or
as a result of such default by the Company in accordance with the procedures set forth in Section 9
herein.

3. Delivery and Payment.

          (a) Prior to the completion of the purchase and sale of the Units pursuant to this Agreement
and the Subscription Agreements (the “Closing”), each such Purchaser shall deposit into an escrow
account (the “Escrow Account”) pursuant to an escrow agreement among the Company, Needham, WBB
Securities and JPMorgan Chase Bank, N.A. (the “Escrow Agent”) dated July ___, 2007, an amount equal
to the product of (x) the number of Units such Purchaser has agreed to purchase and (y) the
purchase price per Unit set forth in the Final Prospectus and the Subscription Agreements (the
“Purchase Amount”). The aggregate of such Purchase Amounts is herein referred to as the “Escrow
Funds”. On the Closing Date, upon satisfaction or waiver of all of the conditions to Closing, the
Escrow Agent will disburse the Escrow Funds to the Company and the Placement Agents as provided in
Section 2(e) above, and the Company shall cause the Units to be delivered to the Purchasers.

          (b) Subject to the terms and conditions hereof, delivery of the Units shall be made by the
Company to the Purchasers, and payment of the purchase price shall be made by the Purchasers, at
the office of Pepper Hamilton LLP, 400 Berwyn Park, 899 Cassatt Road, Berwyn, PA 19312-1183 (or at
such other place as agreed upon by the Placement Agents and the Company), at 10:00 a.m., New York
City time, on or before                 , 2007 or at such time on such other date as may be agreed upon in
writing by the Company and the Placement Agents but in no event prior to the date on which the
Escrow Agent shall have received all of the Escrow Funds (such date of delivery and payment is
hereinafter referred to as the “Closing Date”). The Shares shall be delivered, through the
facilities of The American Stock Transfer & Trust Company, to such persons, and shall be registered
in such name or names and shall be in such denominations, as the Placement Agents may request by
written notice to the Company at least two business days before the Closing Date. The cost of
original issue tax stamps and other transfer taxes, if any, in connection with the issuance and
delivery of the Units by the Company to the respective Purchasers shall be borne by the Company.

4. Representations and Warranties of the Company. The Company represents and warrants to, and agrees with, the Placement Agents that:

          (a) Filing and Effectiveness of Registration Statement; Certain Defined Terms. The Company has
filed with the Commission a registration statement on Form SB-2 (No.333-142787), including a
related prospectus or prospectuses, covering the registration of the Units under the Act, which
registration statement has become effective. “Registration Statement” at any particular time means
such registration statement in the form then filed with the Commission, including any amendment
thereto, any document incorporated by reference therein and all, if applicable, 430B Information or
all 430C Information with respect to such registration statement, that in any case has not been
superseded or modified. “Registration Statement” without reference to a time means the Registration
Statement as of the Effective Date. For purposes of this definition, 430B Information shall be
considered to be included in the Registration Statement as of the time specified in Rule 430B.

For purposes of this Agreement:

“430B Information” means information included in a prospectus then deemed to be a part of the
Registration Statement pursuant to Rule 430B(e) or retroactively deemed to be a part of the
Registration Statement pursuant to Rule 430B(f).

“430C Information” means information included in a prospectus then deemed to be a part of the
Registration Statement pursuant to Rule 430C.

“Act” means the Securities Act of 1933, as amended.

“Applicable Time” means            p.m. (Eastern time) on the date of this Agreement.

- 2 -

 

“Closing Date” has the meaning defined in Section 3 hereof.

“Commission” means the Securities and Exchange Commission.

“Effective Date” of the Registration Statement relating to the Units means the earlier of (a) first
use of the Final Prospectus and (b) the time of the first contract of sale for the Units.

“Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time..

“Final Prospectus” means the Statutory Prospectus that discloses the public offering price, other
430B Information and other final terms of the Units and otherwise satisfies Section 10(a) of the
Act.

“General Use Issuer Free Writing Prospectus” means any Issuer Free Writing Prospectus that is
intended for general distribution to prospective investors, as evidenced by its being so specified
in Schedule A to this Agreement.

“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule
433, relating to the Units in the form filed or required to be filed with the Commission or, if not
required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g).

“Limited Use Issuer Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not a
General Use Issuer Free Writing Prospectus.

“Rules and Regulations” means the rules and regulations of the Commission.

“Securities Laws” means, collectively, the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”), the Act,
the Exchange Act, the Rules and Regulations, the auditing principles, rules, standards and
practices applicable to auditors of “issuers” (as defined in Sarbanes-Oxley) promulgated or
approved by the Public Company Accounting Oversight Board and, as applicable, the rules of the New
York Stock Exchange, The NASDAQ Stock Market, the American Stock Exchange and the Over-the-Counter
Bulletin Board (“Exchange Rules”).

“Statutory Prospectus” with reference to any particular time means the prospectus relating to the
Units that is included in the Registration Statement immediately prior to that time, including any
document incorporated by reference therein and all 430B Information and all 430C Information with
respect to the Registration Statement. For purposes of the foregoing definition, 430B Information
shall be considered to be included in the Statutory Prospectus only as of the actual time that form
of prospectus (including a prospectus supplement) is filed with the Commission pursuant to Rule
424(b) and not retroactively.

Unless otherwise specified, a reference to a “Rule” is to the indicated rule under the Act.

          (b) Compliance with Securities Act Requirements. (i) (A) At the time the Registration
Statement initially became effective, (B) at the time of each amendment thereto for the purposes of
complying with Section 10(a)(3) of the Act (whether by post-effective amendment, incorporated
report or form of prospectus), (C) on the Effective Date relating to the Units and (D) on the
Closing Date, the Registration Statement conformed and will conform in all material respects to the
requirements of the Act and the Rules and Regulations and did not and will not include any untrue
statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein not misleading and (ii) (A) on its date, (B) at the time
of filing the Final Prospectus pursuant to Rule 424(b) and (C) on the Closing Date, the Final
Prospectus will conform in all material respects to the requirements of the Act and the Rules and
Regulations, and will not include any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The preceding sentence does not apply to statements in
or omissions from any such document based upon written information furnished to the Company by the
Placement Agents, if any, specifically for use therein, it being understood and agreed that the
only such information is that described as such in Section 9(b) and Schedule B hereof.

          (c) General Disclosure Package. As of the Applicable Time, neither (i) the General Use Issuer
Free Writing Prospectus(es) issued at or prior to the Applicable Time, any preliminary prospectus
supplement, together with the accompanying prospectus and any other documents listed or disclosures
stated in Schedule A to this Agreement to be included in the General Disclosure Package, all
considered together (collectively, the “General Disclosure Package”), nor (ii) any individual
Limited Use Issuer Free Writing Prospectus, when considered together with the General Disclosure
Package, included any untrue statement of a material fact or omitted to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The preceding sentence does not apply to statements in or omissions
from any Statutory Prospectus or any Issuer Free Writing Prospectus in reliance upon and in
conformity with written information furnished to the Company by the Placement Agents specifically
for use therein, it being understood and agreed that the only such information furnished by the
Placement Agents consists of the information described as such in Section 9(b) and Schedule
B hereof.

- 3 -

 

          (d) Issuer Free Writing Prospectuses. Each Issuer Free Writing Prospectus, if any, as of its
issue date and at all subsequent times through the completion of the public offer and sale of the
Units or until any earlier date that the Company notified or notifies the Placement Agents as
described in the next sentence, did not, does not and will not include any information that
conflicted, conflicts or will conflict with the information then contained in the Registration
Statement. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or
occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted
or would conflict with the information then contained in the Registration Statement or as a result
of which such Issuer Free Writing Prospectus, if republished immediately following such event or
development, would include an untrue statement of a material fact or omitted or would omit to state
a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading, (i) the Company has promptly notified or
will promptly notify the Placement Agent and (ii) the Company has promptly amended or will promptly
amend or supplement such Issuer Free Writing Prospectus to eliminate or correct such conflict,
untrue statement or omission. The foregoing two sentences do not apply to statements in or
omissions from any Issuer Free Writing Prospectus in reliance upon and in conformity with written
information furnished to the Company by the Placement Agents specifically for use therein, it being
understood and agreed that the only such information furnished by the Placement Agents consists of
the information described as such in Section 9(b) and Schedule B hereof.

          (e) Good Standing of the Company and its Subsidiary.

               (i) The Company has been duly incorporated and is existing and in good standing under the laws
of the State of Delaware, with power and authority (corporate and other) to own its properties and
conduct its business as described in the General Disclosure Package and the Final Prospectus; and
the Company is duly qualified to do business as a foreign corporation in good standing in all other
jurisdictions in which its ownership or lease of property or the conduct of its business requires
such qualification, except to the extent that the failure to be so qualified or be in good standing
would not materially and adversely affect the Company or its businesses, properties, business
prospects, conditions (financial or other) or results of operations, taken as a whole (such effect
is referred to herein as a “Material Adverse Effect”).

               (ii) The Company’s subsidiary, as listed in the General Disclosure Package (the “Company
Subsidiary”), is a corporation or other legal entity duly organized, validly existing and in good
standing under the laws of the jurisdiction of its incorporation or organization and has all
requisite corporate (or similar) power and authority and all necessary governmental approvals to
own, lease and operate its properties and to carry on its business as now being conducted, except
where the failure to have such governmental approvals would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. The Company Subsidiary is duly qualified
or licensed to do business and is in good standing in each jurisdiction in which the nature or
conduct of its business or the ownership, leasing or operation of its properties requires it to be
so qualified, licensed or to be in good standing, except for such jurisdictions where the failure
to be so qualified, licensed or to be in good standing would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.

          (f) Subsidiaries. Except as set forth in the General Disclosure Package, the Company has no
subsidiary that is a “significant subsidiary” of the Company within the meaning of Rule 1.02(w) of
Regulation S-X of the Rules and Regulations.

          (g) Capital Stock. The Shares to be issued and sold by the Company to the Purchasers hereunder
and under the Subscription Agreements and the shares of Common Stock issuable upon exercise of the
Warrants (the “Warrant Shares”) and all other outstanding shares of capital stock of the Company
have been duly authorized; all outstanding shares of capital stock of the Company are, and, when
the Shares of Common Stock have been delivered and paid for in accordance with this Agreement and
the Subscription Agreements on the Closing Date and the Warrant Shares have been delivered and paid
for in accordance with the Warrants, such shares will have been validly issued, fully paid and
nonassessable, will conform to the information in the General Disclosure Package and to the
description of such shares contained in the Final Prospectus; the stockholders of the Company have
no statutory or contractual preemptive rights with respect to its Common Stock; none of the
outstanding shares of capital stock of the Company are or will have been issued in violation of any
statutory or contractual preemptive rights of any security holder; and the authorized equity
capitalization of the Company is as set forth in the General Disclosure Package.

          (h) No Finder’s Fee. Except for the transactions contemplated by this Agreement, there are no
contracts, agreements or understandings between the Company and any person that would give rise to
a valid claim against the Company or the Placement Agents for a brokerage commission, finder’s fee
or other like payment.

          (i) Financial Statements. The financial statements and schedules included or incorporated by
reference in the Registration Statement, the General Disclosure Package and the Final Prospectus
present fairly in all material respects the financial condition of the Company and its consolidated
subsidiaries as of the respective dates thereof and the results of operations and cash flows of the
Company and its consolidated subsidiaries for the respective periods covered thereby, all in

- 4 -

 

conformity with generally accepted accounting principles applied on a consistent basis
throughout the entire period involved. No other financial statements or schedules of the Company
are required by the Act, the Exchange Act, or the Rules and Regulations to be included in the
Registration Statement, the General Disclosure Package or the Final Prospectus. Deloitte & Touche
LLP (“Accountants”), who have reported on such financial statements and schedules, are independent
accountants with respect to the Company as required by the Act and the Rules and Regulations and
Rule 3600T of the Public Company Accounting Oversight Board (“PCAOB”). The summary and selected
financial data included in the Registration Statement present fairly in all material respects the
information shown therein and have been compiled on a basis consistent with the audited financial
statements presented in the Registration Statement.

          (j) Absence of Changes. Subsequent to the respective dates as of which information is given in
the Registration Statement and the General Disclosure Package and prior to or on the Closing Date,
except as set forth in or contemplated by the Registration Statement and the General Disclosure
Package, (i) there has not been and will not have been any change in the capitalization of the
Company (other than in connection with the grant or exercise of options to purchase the Common
Stock granted pursuant to the Company’s stock option plans from the shares reserved therefor, or
the issuance of shares under the Company’s existing employee stock purchase plan as described in
the Registration Statement), or any Material Adverse Effect arising for any reason whatsoever, (ii)
neither the Company nor the Company Subsidiary has incurred or will incur, except in the ordinary
course of business as described in the General Disclosure Package, any material liabilities or
obligations, direct or contingent, neither the Company nor the Company Subsidiary has entered into
or will enter into, except in the ordinary course of business as described in the General
Disclosure Package, any material transactions other than pursuant to this Agreement and the
transactions referred to herein and (iii) the Company has not and will not have paid or declared
any dividends or other distributions of any kind on any class of its capital stock.

          (k) Not An Investment Company. Neither the Company nor the Company Subsidiary is or will
become as a result of the transactions contemplated hereby, an “investment company” or an
“affiliated person” of, or “promoter” or “principal underwriter” for, an “investment company,” as
such terms are defined in the Investment Company Act of 1940, as amended.

          (l) Litigation. There are no actions, suits or proceedings pending or, to the knowledge of the
Company, threatened against or affecting the Company or the Company Subsidiary or against any of
the Company’s officers in their capacity as such, before or by any federal or state court,
commission, regulatory body, administrative agency or other governmental body, domestic or foreign,
wherein an unfavorable ruling, decision or finding would reasonably be expected to have a Material
Adverse Effect.

          (m) Absence of Existing Defaults and Conflicts. Neither the Company nor the Company Subsidiary
is (i) in violation of any provision of its certificate of incorporation or bylaws, (ii) in default
in any respect, and no event has occurred which, with notice or lapse of time or both, would
constitute such a default, in the due performance or observance of any indenture, contract, lease,
mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition,
covenant or instrument to which it is a party or by which it is bound or to which any of its
property or assets is subject, or (iii) in violation in any respect of any statute, law, rule,
regulation, ordinance, judgment, order or decree of any court, regulatory body, administrative
agency, governmental body, arbitrator or other authority having jurisdiction over the Company, the
Company Subsidiary or any of their respective properties, as applicable, except, with respect to
clauses (ii) and (iii), any violations or defaults which, individually or in the aggregate, would
not reasonably be expected to have a Material Adverse Effect.

          (n) Absence of Further Requirements. No consent, approval, authorization or order of, or any
filing or declaration with, any court or governmental agency or body is required for the
consummation by the Company of the transactions on its part contemplated herein, the Subscription
Agreements or the Warrants, including the offering and sale of the Units, except such as have been
obtained under the Act or the Rules and Regulations and such as may be required under state
securities or Blue Sky laws or the bylaws and rules of the NASD in connection with the offering of
the Units.

          (o) Authorization; Absence of Defaults and Conflicts Resulting from Transaction. The Company
has full corporate power and authority to enter into this Agreement, each of the Subscription
Agreements and each of the Warrants. Each of this Agreement, the Subscription Agreements and the
Warrants has been duly authorized, executed and delivered by the Company. The Subscription
Agreements and the Warrants are valid and binding agreements of the Company, enforceable against
the Company in accordance with their respective terms. The performance of each of this Agreement,
each Subscription Agreement and each Warrant and the consummation of the transactions contemplated
hereby and thereby, will not (i) result in the creation or imposition of any lien, charge or
encumbrance upon any of the assets of the Company pursuant to the terms or provisions of, or result
in a breach or violation of any of the terms or provisions of, or conflict with or constitute a
default under, or give any party a right to terminate any of its obligations under, or result in
the acceleration of any obligation under, (A) the certificate of incorporation or bylaws of the
Company, or (B) any indenture, mortgage, deed of

- 5 -

 

trust, voting trust agreement, loan agreement, bond, debenture, note agreement or other
evidence of indebtedness, lease, contract or other agreement or instrument to which the Company or
the Company Subsidiary is a party or by which the Company or any of its properties is bound or
affected, except, in the case of clause (i)(B), any lien, breach, violation, conflict, default or
acceleration that, would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, or (ii) violate or conflict with any judgment, ruling, decree, order,
statute, rule or regulation of any court or other governmental agency or body applicable to the
business or properties of the Company or the Company Subsidiary, as applicable.

          (p) Title to Property. The Company, or the Company Subsidiary, as applicable, has good and
marketable title to all properties and assets described in the General Disclosure Package and Final
Prospectus as owned by it, free and clear of all liens, charges, encumbrances or restrictions,
except such as are not material to the business of the Company. The Company, or the Company
Subsidiary, as applicable, has valid, subsisting and enforceable leases for the properties
described in the General Disclosure Package and Final Prospectus as leased by it. The Company, or
the Company Subsidiary, as applicable, owns or leases all such properties as are necessary to its
operations as now conducted or as proposed to be conducted, except where the failure to so own or
lease would not reasonably be expected to have a Material Adverse Effect.

          (q) Off Balance Sheet Interests and Contracts. There is no document, contract, permit or
instrument, affiliate transaction or off-balance sheet transaction (including, without limitation,
any “variable interests” in “variable interest entities,” as such terms are defined in Financial
Accounting Standards Board Interpretation No. 46) of a character required to be described in the
Registration Statement or the General Disclosure Package or to be filed as an Exhibit to the
Registration Statement that is not described or filed as required. All such contracts described in
the immediately preceding sentence to which the Company is a party have been duly authorized,
executed and delivered by the Company, constitute valid and binding agreements of the Company and
are enforceable against and by the Company in accordance with the terms thereof.

          (r) Accuracy of Statements. No statement, representation, warranty or covenant made by the
Company or the Company Subsidiary, if applicable, in this Agreement or any Subscription Agreement
or made in any certificate or document required by Section 7 of this Agreement to be delivered to
the Placement Agents was or will be, when made, inaccurate, untrue or incorrect in any material
respect.

          (s) Offering Material; Stabilization. The Company has not distributed, and will not distribute
prior to the Closing Date, any offering material in connection with the offering and sale of the
Units other than any preliminary prospectuses, any Permitted Free Writing Prospectus (as defined in
Section 6 below), the Final Prospectus, the Registration Statement and other materials, if any,
permitted by the Act. Neither the Company nor any of its directors, officers or controlling persons
has taken, directly or indirectly, any action designed, or that might reasonably be expected, to
cause or result, under the Act or otherwise, in, or that has constituted, stabilization or
manipulation of the price of any security of the Company to facilitate the sale or resale of the
Units.

          (t) Registration Rights. Except as set forth in the General Disclosure Package, no holder of
securities of the Company has rights to the registration of any securities of the Company in
connection with the Offering, which rights have not been waived by the holder thereof as of the
date hereof.

          (u) Listing. The Common Stock is registered under Section 12(g) of the Exchange Act and is
traded on the Over –the-Counter Bulletin Board.

          (v) Possession of Intellectual Property. Except as specifically disclosed in the General
Disclosure Package, (i) the Company, either directly or indirectly through the Company Subsidiary,
owns or has adequate rights to use all trademarks, trade names, domain names, patents, patent
rights, copyrights, technology, know-how (including trade secrets and other unpatented or
unpatentable proprietary or confidential information, systems or procedures), service marks, trade
dress rights, and other intellectual property (collectively, “Intellectual Property”) and, to the
Company’s knowledge, has such other licenses, approvals and governmental authorizations, in each
case sufficient to conduct its business as now conducted and as now proposed to be conducted, and
to the Company’s knowledge, none of the foregoing Intellectual Property rights owned or licensed by
the Company is invalid or unenforceable, (ii) the Company has no knowledge of any infringement by
it of Intellectual Property rights of others, (iii) the Company is not aware of any infringement,
misappropriation or violation by others of, or conflict by others with rights of the Company with
respect to, any Intellectual Property, (iv) there is no claim being made against the Company or, to
the best knowledge of the Company, any employee of the Company, regarding Intellectual Property or
other infringement, and (v) the Company has not received any notice of infringement with respect to
any patent or any notice challenging the validity, scope or enforceability of any Intellectual
Property owned by or licensed to the Company.

          (w) Taxes. The Company and the Company Subsidiary have each filed all federal, state, local
and foreign income tax returns that have been required to be filed and have paid all taxes and
assessments received by it to the extent that

- 6 -

 

such taxes or assessments have become due. Neither the Company nor the Company Subsidiary have
a tax deficiency that has been or, to the best knowledge of the Company, might be asserted or
threatened against it that would reasonably be expected to have a Material Adverse Effect.

          (x) Permits, Licenses and Regulatory Authorizations. The Company, either directly or
indirectly through the Company Subsidiary, owns or possesses all authorizations, approvals, orders,
licenses, registrations, other certificates and permits of and from all appropriate federal, state
or foreign regulatory officials and bodies, including without limitation, the United States Food
and Drug Administration (the “FDA”) necessary to conduct its current operations as contemplated in
the General Disclosure Package, except where the failure to own or possess all such authorizations,
approvals, orders, licenses, registrations, other certificates and permits would not reasonably be
expected to have a Material Adverse Effect. There is no proceeding pending or threatened (or any
basis therefor known to the Company) that may cause any such authorization, approval, order,
license, registration, certificate or permit to be revoked, modified, withdrawn, cancelled,
suspended or not renewed, except where such modification, revocation, withdrawal, cancellation,
suspension or non-renewal would not reasonably be expected to have a Material Adverse Effect; and
the Company is conducting its current operations in compliance with all laws, rules and regulations
applicable thereto, except where such noncompliance would not reasonably be expected to have a
Material Adverse Effect.

          (y) FCPA Compliance. Neither the Company nor the Company Subsidiary has and, to the best of
the Company’s knowledge, none of its employees or agents at any time during the last five years
have (i) made any unlawful contribution to any candidate for foreign office, or failed to disclose
fully any contribution in violation of law, or (ii) made any payment to any federal or state
governmental officer or official, or other person charged with similar public or quasi-public
duties, other than payments required or permitted by the laws of the United States or any
jurisdiction thereof.

          (z) Internal Controls and Compliance With Sarbanes-Oxley Act. The books, records and accounts
of the Company accurately and fairly reflect in all material respects, in reasonable detail, the
transactions in, and dispositions of, the assets of, and the results of operations of, the Company
and its consolidated subsidiaries. The principal executive officer and principal financial officer
of the Company have made all certifications required by Sections 302 and 906 of Sarbanes-Oxley and
the rules and regulations promulgated in connection therewith with respect to all reports,
schedules, forms, statements and other documents required to be filed by it with the Commission,
and the statements contained in any such certification are complete and correct. For purposes of
the preceding sentence, “principal executive officer” and “principal financial officer” shall have
the meanings given to such terms in Sarbanes-Oxley. The Company maintains (x) systems of internal
accounting controls sufficient to provide reasonable assurances that (i) transactions are executed
in accordance with management’s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of the Company’s consolidated financial statements in accordance
with generally accepted accounting principles and to maintain asset accountability, (iii) access to
assets is permitted only in accordance with management’s general or specific authorization, and
(iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences, and (y) disclosure
controls and procedures (as defined in Rule 13a-14(c) under the Exchange Act); such disclosure
controls and procedures have been designed to ensure that material information relating to the
Company and its subsidiaries is made known to the Company’s principal executive officer and
principal financial officer by others within those entities; and such disclosure controls and
procedures are effective.

          (aa) ERISA Compliance. The Company has fulfilled in all material respects its obligations, if
any, under the minimum funding standards of Section 302 of the United States Employee Retirement
Income Security Act of 1974 (“ERISA”) and the regulations and published interpretations thereunder
with respect to each “plan” (as defined in Section 3(3) of ERISA and such regulations and published
interpretations) in which employees of the Company are eligible to participate and each such plan
is in compliance in all material respects with the presently applicable provisions of ERISA and
such regulations and published interpretations. No “prohibited transaction” (as defined in Section
406 of ERISA, or Section 4975 of the Internal Revenue Code of 1986, as amended from time to time
(the “Code”)) has occurred with respect to any employee benefit plan which would reasonably be
expected to result in a Material Adverse Effect.

          (bb) Labor Issues. No labor problem or dispute with the employees of the Company exists or, to
the Company’s knowledge, is threatened or imminent, which would reasonably be expected to result in
a Material Adverse Effect. The Company is not aware that any key employee or significant group of
employees of the Company plans to terminate employment with the Company.

          (cc) Statistical and Market-Related Data. Any third-party statistical and market-related data
included or incorporated by reference in the Registration Statement, a Statutory Prospectus or the
General Disclosure Package are based on or derived from sources that the Company believes to be
reliable and accurate.

          (dd) Forward-Looking Statements. No forward-looking statement (within the meaning of Section
27A of the Securities Act and Section 21E of the Exchange Act) contained in the Registration
Statement, the General Disclosure

- 7 -

 

Package or the Final Prospectus has been made or reaffirmed without a reasonable basis or has
been disclosed other than in good faith.

          (ee) Environmental Laws. The Company and the Company Subsidiary (i) is in compliance with any
and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders
relating to the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (ii) has
received and is in compliance with all permits, licenses or other approvals required of them under
applicable Environmental Laws to conduct its business; and (iii) has not received notice of any
actual or potential liability for the investigation or remediation of any disposal or release of
hazardous or toxic substances or wastes, pollutants or contaminants, except in the case of
subsections (i), (ii) and (iii) of this subsection (gg) as would not, individually or in the
aggregate, have a Material Adverse Effect.

          (ff) Conduct of Clinical Trials. The studies, tests and preclinical and clinical trials
conducted by or on behalf of the Company that are described in the General Disclosure Package or
the Final Prospectus were and, if still pending, are being conducted in accordance in all material
respects with all statutes, laws, rules and regulations, as applicable (including, without
limitation, those administered by the FDA or by any foreign, federal, state or local governmental
or regulatory authority performing functions similar to those performed by the FDA) and with
standard medical and scientific research procedures. The descriptions of the studies, tests and
preclinical and, if applicable, clinical trials, including the related results and regulatory
status, contained in the General Disclosure Package or the Final Prospectus are accurate in all
material respects. The Company has not received any notices, correspondence or other communication
from the FDA or other governmental agency requiring the termination or suspension of any clinical
trials, if applicable, conducted by, or on behalf of, the Company or in which the Company has
participated.

          (gg) Business of Subsidiaries. Except as set forth in the General Disclosure Package, none of
the Company’s subsidiaries owns any assets, has any liabilities or conducts any business.

          (hh) NASD Affiliations. Except as set forth in the General Disclosure Package, to the
Company’s knowledge, there are no affiliations or associations between (i) any member of the NASD
and (ii) the Company or any of the Company’s officers, directors or 5% or greater securityholders
or any beneficial owner of the Company’s unregistered equity securities that were acquired from the
Company at any time on or after the one hundred and eightieth (180th) day immediately
preceding the date of the Registration Statement was initially filed with the Commission.

5. Representations and Warranties of the Placement Agents. The Placement Agents, jointly and
severally, represent and warrant to, and agree with, the Company that:

          (a) Each Placement Agent is a member in good standing of the NASD and has, and at all times
while taking any actions constituting an offer or sale of the Units had, all governmental licenses
(including both federal and state broker dealer licenses) required to act as placement agent for
the Units.

          (b) Each Placement Agent has complied, in all material respects, with all applicable Federal
and state laws and applicable rules of the NASD in connection with its activities as placement
agent for the Units.

          (c) No Placement Agent has delivered any materials to the Purchasers relating to the Company
other than those that are “communications not deemed a prospectus,” pursuant to Rule 134 or a
prospectus meeting the requirements of Section 10 of the Securities Act and no Placement Agent has
made any statement or communication in connection with the offer and sale of the Units inconsistent
or in conflict any Statutory Prospectus.

6. Certain Agreements of the Company. The Company agrees with the Placement Agents that it will
furnish to counsel for the Placement Agents one copy of the Registration Statement relating to the
Units, including all exhibits, in the form it became effective and of all amendments thereto and
that, in connection with the offering of Units:

          (a) Filing of Prospectuses. The Company has filed or will file each Statutory Prospectus
(including the Final Prospectus) pursuant to and in accordance with Rule 424(b)(2) (or, if
applicable and consented to by the Placement Agent, subparagraph (b)(5)) not later than the second
business day following the earlier of the date it is first used or the date of this Agreement. The
Company has complied and will comply with Rule 433.

          (b) Filing of Amendments; Response to Commission Requests. The Company will promptly advise
the Placement Agents of any proposal to amend or supplement the Registration Statement or any
Statutory Prospectus until the completion of the purchase and sale of the Units contemplated herein
and will afford the Placement Agents a reasonable opportunity to comment on any such proposed
amendment or supplement; and the Company will also advise the Placement Agents promptly of (i) the
filing of any such amendment or supplement, (ii) any request by the Commission or its staff for any
amendment to the Registration Statement, for any supplement to any Statutory Prospectus or for any
additional

- 8 -

 

information, (iii) the institution by the Commission of any stop order proceedings in respect
of the Registration Statement or the threatening of any proceeding for that purpose, and (iv) the
receipt by the Company of any notification with respect to the suspension of the qualification of
the Units (including the Shares and Warrant Shares) in any jurisdiction or the institution or
threatening of any proceedings for such purpose. The Company will use its best efforts to prevent
the issuance of any such stop order or the suspension of any such qualification and, if issued, to
obtain as soon as possible the withdrawal thereof.

          (c) Continued Compliance with Securities Laws. If, at any time when a prospectus relating to
the Units is (or but for the exemption in Rule 172 under the Act would be) required to be delivered
under the Act in connection with sales by the Company to any Purchasers, any event occurs as a
result of which the Final Prospectus as then amended or supplemented would include an untrue
statement of a material fact or omit to state any material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, or if it is
necessary at any time to amend the Registration Statement or supplement the Final Prospectus to
comply with the Act, the Company will promptly notify the Placement Agents of such event and will
promptly prepare and file with the Commission and furnish, at its own expense, to the Placement
Agents and, to the extent applicable, the dealers and any other dealers upon request of the
Placement Agents, an amendment or supplement which will correct such statement or omission or an
amendment which will effect such compliance. Neither the Placement Agents’ consent to, nor the
Placement Agents’ delivery of, any such amendment or supplement shall constitute a waiver of any of
the conditions set forth in Section 7 hereof.

          (d) Rule 158. As soon as practicable, but not later than 16 months, after the date of this
Agreement, the Company will make generally available to its securityholders an earnings statement
covering a period of at least 12 months beginning after the date of this Agreement and satisfying
the provisions of Section 11(a) of the Act and Rule 158.

          (e) Furnishing of Prospectuses. The Company will furnish to the Placement Agents copies of the
Registration Statement, including all exhibits, any Statutory Prospectus relating to the Units, the
Final Prospectus and all amendments and supplements to such documents, in each case as soon as
available and in such quantities as the Placement Agents reasonably request. The Company will pay
the expenses of printing and distributing to the Placement Agents all such documents.

          (f) Blue Sky Qualifications. The Company will arrange for the qualification of the Units for
sale under the laws of such jurisdictions as the Placement Agents designate and will continue such
qualifications in effect so long as required for the distribution; provided that the Company will
not be required to qualify as a foreign corporation or to file a general consent to service of
process in any such jurisdiction or take any action that would subject it to taxation in any such
jurisdiction where it is not then so subject.

          (g) Reporting Requirements. During the period of five years after the date of the this
Agreement, the Company will furnish to the Placement Agents as soon as practicable after the end of
each fiscal year, a copy of its annual report to stockholders for such year; and the Company will
furnish to the Placement Agent (i) as soon as available, a copy of each report and any definitive
proxy statement of the Company filed with the Commission under the Exchange Act or mailed to
stockholders, and (ii) from time to time, such other information concerning the Company as the
Placement Agent may reasonably request. However, so long as the Company is subject to the reporting
requirements of either Section 13 or Section 15(d) of the Exchange Act and is timely filing reports
with the Commission on its Electronic Data Gathering, Analysis and Retrieval system (“EDGAR”), it
is not required to furnish such reports or statements to the Placement Agents.

          (h) Payment of Expenses. The Company will pay all fees and expenses incident to the
performance of the its obligations under this Agreement, including but not limited to (i) any
filing fees and other expenses (including reasonable fees and disbursements of counsel to the
Placement Agents) incurred in connection with qualification of the Units for sale under the laws of
such jurisdictions as the Placement Agents may designate and the preparation and printing of
memoranda relating thereto, (ii) any costs and expenses related to, the review by the NASD of the
Units (including filing fees and the reasonable fees and dispursements of counsel for the Placement
Agent relating to such review), (iii) any travel expenses of the Company’s officers and employees
and any other expenses of the Company in connection with attending or hosting meetings with
prospective purchasers of the Units, (iv) fees and expenses incident to listing the Shares on any
national and foreign exchanges, (v) fees and expenses in connection with the registration of the
Units under the Exchange Act, (vi) fees and expenses incurred in distributing any Statutory
Prospectuses and the Final Prospectus (including any amendments and supplements thereto) to the
Placement Agents and for expenses incurred for preparing, printing and distributing any Issuer Free
Writing Prospectuses to investors or prospective investors, (vii) subject to Section 6(h)(viii),
the reasonable and documented out-of-pocket expenses of the Placement Agents incurred in the
performance of their duties hereunder (collectively with all other reasonable and documented fees
and expenses owed to the Placement Agents pursuant to this Section 6(h), the “Placement Agent
Expenses”), (viii) the documented fees and disbursements of the Placement Agents’ counsel,
provided that in no event shall the Company be obligated to pay the fees and disbursements of
counsel to the Placement Agents under this Section 6(h) in an amount greater than $100,000 unless
otherwise agreed by the Company and

- 9 -

 

(ix) all other costs and expenses incurred by the Company incident to the performance of the
obligations of the Company hereunder for which provision is not otherwise made in this Section
6(h).

          (i) Use of Proceeds. The Company will use the net proceeds received in connection with any
offering of the Units in the manner described in the “Use of Proceeds” section of the General
Disclosure Package and the Company does not intend to use any of the proceeds from the sale of the
Units hereunder to repay any outstanding debt owed to any affiliate of the Placement Agent.

          (j) Absence of Manipulation. The Company will not take, directly or indirectly, any action
designed to or that would constitute or that might reasonably be expected to cause or result in,
stabilization or manipulation of the price of any securities of the Company to facilitate the sale
or resale of the Units.

          (k) Restriction on Sale of Securities. For the period specified below (the “Lock-Up Period”)
and except as disclosed in the General Disclosure Package, the Company will not, directly or
indirectly, take any of the following actions with respect to its Common Stock or any securities
convertible into or exchangeable or exercisable for its Common Stock (“Lock-Up Securities”): (i)
offer, sell, issue, contract to sell, pledge or otherwise dispose of, Lock-Up Securities, (ii)
offer, sell, issue, contract to sell, contract to purchase or grant any option, right or warrant to
purchase Lock-Up Securities, (iii) enter into any swap, hedge or any other agreement that
transfers, in whole or in part, the economic consequences of ownership of Lock-Up Securities, (iv)
establish or increase a put equivalent position or liquidate or decrease a call equivalent position
in Lock-Up Securities within the meaning of Section 16 of the Exchange Act or (v) file with the
Commission a registration statement under the Act relating to Lock-Up Securities, or publicly
disclose the intention to take any such action, without the prior written consent of Needham,
except pursuant to existing contractual rights and obligations and issuances of Lock-Up Securities
pursuant to the conversion of convertible securities or the exercise of warrants or options, in
each case outstanding on the date of this Agreement, grants of employee stock options pursuant to
the terms of a plan in effect on the date of this Agreement, or issuances of Lock-Up Securities
pursuant to the exercise of such options. The initial Lock-Up Period will commence on the date
hereof and continue for 90 days after the date of the commencement of the public offering of the
Units or such earlier date that Needham consents to in writing; provided, however, that if (1)
during the last 17 days of the initial Lock-Up Period, the Company releases earnings results or
material news or a material event relating to the Company occurs or (2) prior to the expiration of
the initial Lock-Up Period, the Company announces that it will release earnings results during the
16-day period beginning on the last day of the initial Lock-Up Period, then in each case the
Lock-Up Period will be extended until the expiration of the 18-day period beginning on the date of
release of the earnings results or the occurrence of the materials news or material event, as
applicable, unless the Placement Agent waives, in writing, such extension. The Company will provide
the Placement Agent with notice of any announcement described in clause (2) of the preceding
sentence that gives rise to an extension of the Lock-Up Period.

7. Free Writing Prospectuses. The Company represents and agrees that, unless it obtains the prior
consent of the Placement Agents, and each Placement Agent, severally and not jointly, represents
and agrees that, unless it obtains the prior written consent of the Company, it has not made and
will not make any offer relating to the Units that would constitute an Issuer Free Writing
Prospectus, or that would otherwise constitute a “free writing prospectus,” as defined in Rule 405,
required to be filed with the Commission. Any such free writing prospectus consented to by the
Company and the Placement Agents, each of which is set forth on Schedule A hereto, is hereinafter
referred to as a “Permitted Free Writing Prospectus.” The Company represents that it has treated
and agrees that it will treat each Permitted Free Writing Prospectus as an “issuer free writing
prospectus,” as defined in Rule 433, and has complied and will comply with the requirements of
Rules 164 and 433 applicable to any Permitted Free Writing Prospectus, including timely Commission
filing where required, legending and record keeping.

8. Conditions of the Obligations of the Placement Agents. The obligations of the Placement Agents
hereunder will be subject to the accuracy of the representations and warranties in all material
respects of the Company herein (as though made on such Closing Date), to the accuracy of the
statements of Company officers made pursuant to the provisions hereof, to the performance by the
Company of its obligations hereunder and to the following additional conditions precedent:

          (a) Accountants’ Comfort Letter. The Placement Agents shall have received letters, dated,
respectively, the date hereof and the Closing Date, of Deloitte & Touche LLP confirming that they
are a registered public accounting firm and independent public accountants within the meaning of
the Securities Laws and substantially in the form of Schedule B hereto (except that, in any letter
dated the Closing Date, the specified date referred to in Schedule B hereto shall be a date no more
than three days prior to the Closing Date).

          (b) Filing of Prospectus. The Final Prospectus shall have been filed with the Commission in
accordance with the Rules and Regulations and Section 6(a) hereof. No stop order suspending the
effectiveness of the Registration Statement or of any part thereof shall have been issued and no
proceedings for that purpose shall have been instituted or, to the knowledge of the Company or the
Placement Agents, shall be contemplated by the Commission.

- 10 -

 

          (c) No Material Adverse Change. Subsequent to the execution and delivery of this Agreement,
there shall not have occurred (i) any changes, or any developments or events involving a
prospective change, in the condition (financial or otherwise), results of operations, business,
properties or prospects of the Company and its subsidiaries taken as a whole which, in the
reasonable judgment of Needham, as representative of the Placement Agents, is material and adverse
and makes it impractical or inadvisable to market the Units; (ii) any downgrading in the rating of
any debt securities of the Company by any “nationally recognized statistical rating organization”
(as defined for purposes of Rule 436(g)), or any public announcement that any such organization has
under surveillance or review its rating of any debt securities of the Company (other than an
announcement with positive implications of a possible upgrading, and no implication of a possible
downgrading, of such rating) or any announcement that the Company has been placed on negative
outlook; (iii) any changes in U.S. or international financial, political or economic conditions or
currency exchange rates or exchange controls, the effect of which is such as to make it, in the
reasonable judgment of Needham, impractical to market or to enforce contracts for the sale of the
Units, whether in the primary market or in respect of dealings in the secondary market; (iv) any
suspension or material limitation of trading in securities generally on the New York Stock
Exchange, or any setting of minimum or maximum prices for trading on such exchange; (v) or any
suspension of trading of any securities of the Company on any exchange or in the over-the-counter
market; (vi) any banking moratorium declared by any U.S. federal or New York authorities; (vii) any
major disruption of settlements of securities, payment, or clearance services in the United States
or any other country where such securities are listed or (viii) any attack on, outbreak or
escalation of hostilities or act of terrorism involving the United States, any declaration of war
by Congress or any other national or international calamity or emergency if, in the reasonable
judgment of Needham, the effect of any such attack, outbreak, escalation, act, declaration,
calamity or emergency is such as to make it impractical or inadvisable to market the Units or to
enforce contracts for the sale of the Units.

          (d) Opinion of Counsel for the Company. The Placement Agents shall have received an opinion,
dated such Closing Date, of Pepper Hamilton LLP, counsel for the Company, to the effect set forth
in Exhibit C attached hereto.

          (e) Officer’s Certificate. The Placement Agents shall have received a certificate, dated the
Closing Date, of an executive officer of the Company and a principal financial or accounting
officer of the Company in which such officers shall state that: the representations and warranties
of the Company in this Agreement are true and correct; the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the
Closing Date in all material respects; no stop order suspending the effectiveness of the
Registration Statement or of any part thereof has been issued and no proceedings for that purpose
have been instituted or, to the best of their knowledge and after reasonable investigation, are
contemplated by the Commission; and subsequent to the date of the most recent financial statements
in the Final Prospectus, there has been no material adverse change, nor any development or event
involving a prospective material adverse change, in the condition (financial or otherwise), results
of operations, business, properties or prospects of the Company and its subsidiaries taken as a
whole except as set forth in the Final Prospectus or as described in such certificate.

          (f) Lock-up Agreements. On or prior to the date hereof, the Placement Agent shall have
received lockup letters from each of the executive officers and directors of the Company and select
stockholders of the Company as determined by the Placement Agents in their sole discretion.

          (g) Subscription Agreements; Warrants. The Company shall have entered into the Subscription
Agreements with each of the Purchasers and issued the Warrants to the Purchasers, and such
agreements and Warrants shall be in full force and effect.

          (h) The Company will furnish the Placement Agents with such conformed copies of such opinions,
certificates, letters and documents as the Placement Agents may reasonably request. The Placement
Agents may in their sole discretion waive compliance with any conditions to the obligations of the
Placement Agents under this Agreement.

          (i) The Company shall have furnished to the Placement Agents such certificates, in addition to
those specifically mentioned herein, as the Placement Agents may have reasonably requested as to
the accuracy and completeness at the Closing Date of any statement in the Registration Statement or
the Final Prospectus, as to the accuracy at the Closing Date of the representations and warranties
of the Company herein, as to the performance by the Company of its obligations hereunder, or as to
the fulfillment of the conditions concurrent and precedent to the obligations hereunder of the
Placement Agents.

9. Indemnification and Contribution.

          (a) Indemnification of Placement Agents. The Company will indemnify and hold harmless each
Placement Agent, its partners, members, directors, officers, employees, agents, affiliates and each
person, if any, who controls the Placement Agent within the meaning of Section 15 of the Act or
Section 20 of the Exchange Act (each, an “Indemnified

- 11 -

 

Party”), against any and all losses, claims, damages or liabilities, joint or several, to
which such Indemnified Party may become subject, under the Act, the Exchange Act, other Federal or
state statutory law or regulation or otherwise, insofar as such losses, claims, damages or
liabilities (or actions in respect thereof) arise out of or are based upon (i) any default by the
Company to deliver Units to a Purchaser who has delivered, or has committed to deliver, the
Purchase Amount for Units pursuant to an accepted offer or (ii) any untrue statement or alleged
untrue statement of any material fact contained in any part of the Registration Statement at any
time, any Statutory Prospectus as of any time, the Final Prospectus or any Issuer Free Writing
Prospectus, or arise out of or are based upon the omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein not misleading, and will
reimburse each Indemnified Party for any legal or other expenses reasonably incurred by such
Indemnified Party in connection with investigating or defending against any such loss, claim,
damage, liability, action, litigation, investigation or proceeding whatsoever (whether or not such
Indemnified Party is a party thereto), whether threatened or commenced, and in connection with the
enforcement of this provision with respect to any of the above as such expenses are incurred;
provided, however, that the Company will not be liable in any such case to the extent that any such
loss, claim, damage or liability (A) arises out of or is based upon an untrue statement or alleged
untrue statement in or omission or alleged omission from any of such documents in reliance upon and
in conformity with written information furnished to the Company by the Placement Agents
specifically for use therein, it being understood and agreed that the only such information
furnished by the Placement Agents consists of the information described on Schedule B
hereof, (B) any material violation by any Placement Agent of any applicable broker-dealer rules or
federal or state securities laws or (C) to the extent that it is determined in a final judgment by
a court of competent jurisdiction that such loss, claim, damage or liability resulted directly from
any such act or failure to act undertaken or omitted to be taken by the Placement Agents through
their gross negligence or willful misconduct.

          (b) Indemnification of Company. Each Placement Agent will, severally and not jointly,
indemnify and hold harmless the Company, each of its directors and each of its officers who signs
the Registration Statement and each person, if any, who controls the Company within the meaning of
Section 15 of the Act or Section 20 of the Exchange Act (each, a “Placement Agent Indemnified
Party”), against any losses, claims, damages or liabilities to which such Placement Agent
Indemnified Party may become subject, under the Act, the Exchange Act, other Federal or state
statutory law or regulation or otherwise, insofar as such losses, claims, damages or liabilities
(or actions in respect thereof) arise out of or are based upon any untrue statement or alleged
untrue statement of any material fact contained in any part of the Registration Statement at any
time, any Statutory Prospectus as of any time, the Final Prospectus or any Issuer Free Writing
Prospectus, or arise out of or are based upon the omission or the alleged omission of a material
fact required to be stated therein or necessary to make the statements therein not misleading, in
each case to the extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in conformity with written
information furnished to the Company by such Placement Agent specifically for use therein or (B)
any material violation by any Placement Agent of any applicable broker-dealer rules or federal or
state securities laws, and will reimburse any legal or other expenses reasonably incurred by such
Placement Agent Indemnified Party in connection with investigating or defending against any such
loss, claim, damage, liability, action, litigation, investigation or proceeding whatsoever (whether
or not such Placement Agent Indemnified Party is a party thereto), whether threatened or commenced,
based upon any such untrue statement or omission, or any such alleged untrue statement or omission
as such expenses are incurred, it being understood and agreed that, except as set forth in
Schedule B hereof, no such information has been furnished by any Placement Agent.
Notwithstanding the provisions of this subsection (b), in no event shall any indemnity by any
Placement Agent hereunder (i) exceed the total compensation received by the Placement Agents
pursuant to and in accordance with Section 2(e) or (ii) result from any loss, claim, damage or
liability arising out of the gross negligence or willful misconduct of the Company.

          (c) Actions against Parties; Notification. Promptly after receipt by an indemnified party
under this Section of notice of the commencement of any action, such indemnified party will, if a
claim in respect thereof is to be made against the indemnifying party under subsection 9(a) or (b)
above, notify the indemnifying party of the commencement thereof; but the failure to notify the
indemnifying party shall not relieve it from any liability that it may have under subsection 9(a)
or (b) above except to the extent that it has been materially prejudiced (through the forfeiture of
substantive rights or defenses) by such failure; and provided further that the failure to notify
the indemnifying party shall not relieve it from any liability that it may have to an indemnified
party otherwise than under subsection 9(a) or (b) above. In case any such action is brought against
any indemnified party and it notifies the indemnifying party of the commencement thereof, the
indemnifying party will be entitled to participate therein and, to the extent that it may wish,
jointly with any other indemnifying party similarly notified, to assume the defense thereof, with
counsel satisfactory to such indemnified party (who shall not, except with the consent of the
indemnified party, be counsel to the indemnifying party), and after notice from the indemnifying
party to such indemnified party of its election so to assume the defense thereof, the indemnifying
party will not be liable to such indemnified party under this Section for any legal or other
expenses subsequently incurred by such indemnified party in connection with the defense thereof
other than reasonable costs of investigation. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement of any pending or threatened action
in respect of which

- 12 -

 

any indemnified party is or could have been a party and indemnity could have been sought
hereunder by such indemnified party unless such settlement (i) includes an unconditional release of
such indemnified party from all liability on any claims that are the subject matter of such action
and (ii) does not include a statement as to, or an admission of, fault, culpability or a failure to
act by or on behalf of an indemnified party.

          (d) Contribution. If the indemnification provided for in this Section is unavailable or
insufficient to hold harmless an indemnified party under subsection 9(a) or (b) above, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a
result of the losses, claims, damages or liabilities referred to in subsection 9(a) or (b) above
(i) in such proportion as is appropriate to reflect the relative benefits received by the Company
on the one hand and the Placement Agents on the other from the offering of the Units or (ii) if the
allocation provided by clause (i) above is not permitted by applicable law, in such proportion as
is appropriate to reflect not only the relative benefits referred to in clause (i) above but also
the relative fault of the Company on the one hand and the Placement Agents on the other in
connection with the statements or omissions which resulted in such losses, claims, damages or
liabilities as well as any other relevant equitable considerations. The relative benefits received
by the Company on the one hand and the Placement Agents on the other shall be deemed to be in the
same proportion as the total net proceeds from the offering (before deducting expenses) received by
the Company bear to the total underwriting discounts and commissions received by the Placement
Agents. The relative fault shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company or the Placement Agents and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such untrue statement or omission. The amount paid by an indemnified party as a result of the
losses, claims, damages or liabilities referred to in the first sentence of this subsection (d)
shall be deemed to include any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any action or claim which is the subject of
this subsection (d). Notwithstanding the provisions of this subsection (d), the Placement Agents
shall not be required to contribute any amount in excess of the amount by which total compensation
received by the Placement Agents in accordance with Section 2(e) exceeds the amount of any damages
which the Placement Agents have otherwise been required to pay by reason of such untrue or alleged
untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation. The Company and the Placement Agents agree
that it would not be just and equitable if contribution pursuant to this Section 9(d) were
determined by pro rata allocation or by any other method of allocation which does not take account
of the equitable considerations referred to in this Section 9(d).

          (e) Control Persons. The obligations of the Company under this Section shall be in addition to
any liability which the Company may otherwise have and shall extend, upon the same terms and
conditions, to each person, if any, who controls any Placement Agent within the meaning of the Act;
and the obligations of the Placement Agents under this Section shall be in addition to any
liability which the Placement Agents may otherwise have and shall extend, upon the same terms and
conditions, to each director of the Company, to each officer of the Company who has signed the
Registration Statement and to each person, if any, who controls the Company within the meaning of
the Act.

10. Survival of Certain Representations and Obligations. The respective indemnities, agreements,
representations, warranties and other statements of the Company or its officers and of the
Placement Agents set forth in or made pursuant to this Agreement will remain in full force and
effect, regardless of any investigation, or statement as to the results thereof, made by or on
behalf of the Placement Agents, the Company or any of their respective representatives, officers or
directors or any controlling person, and will survive delivery of and payment for the Units. If the
sale and issuance of the Units by the Company hereunder are not consummated for any reason, other
than by a material breach of this Agreement by any Placement Agent, the Company will reimburse the
Placement Agents for the Placement Agent Expenses (including fees and disbursements of counsel
pursuant to Section 6(h) hereof) reasonably incurred as of the date on which the Company notifies
the Placement Agents in writing that it has decided not to consummate the sale and issuance of the
Units in connection with the offering of the Units, and the respective obligations of the Company
and the Placement Agents pursuant to Section 9 hereof shall remain in effect. In addition, if any
Units have been purchased under this Agreement and the Subscription Agreements, the representations
and warranties in Section 4 hereof and all obligations under Section 6 hereof shall also remain in
effect.

11. Notices. All communications hereunder will be in writing and, if sent to the Placement Agent,
will be mailed, delivered or telegraphed and confirmed to (a) Needham & Company, LLC, 445 Park
Avenue, New York, NY 10022, Attention: Corporate Finance Department, and (b) WBB Securities, LLC,
16835 West Bernardo Drive, Suite 203, San Diego, CA 92127, Attention: Corporate Finance Department
or, if sent to the Company, will be mailed, delivered or telegraphed and confirmed to it at 170 N.
Radnor-Chester Road, Suite 300, Radnor PA 19087, Attention: Edward F. Smith, Chief Financial
Officer with a copy to Pepper Hamilton, LLP, 400 Berwyn Park, 899 Cassatt Avenue, Berwyn, PA 19312,
Attention: Jeffrey P. Libson.

- 13 -

 

12. Successors. This Agreement will inure to the benefit of and be binding upon parties hereto and
their respective successors and the officers and directors and controlling persons referred to in
Section 9, and no other person will have any right or obligation hereunder.

13. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall
be deemed to be an original, but all such counterparts shall together constitute one and the same
Agreement.

14. Absence of Fiduciary Relationship. The Company acknowledges and agrees that:

          (a) No Other Relationship. The Placement Agents have been retained solely to act as placement
agents in connection with the sale of Units and that no fiduciary, advisory or agency relationship
between the Company and the Placement Agents has been created in respect of any of the transactions
contemplated by this Agreement, any Subscription Agreement or the Final Prospectus, irrespective of
whether the Placement Agents have advised or are advising the Company on other matters;

          (b) Arm’s-Length Negotiations. The price of the Units set forth in the Final Prospectus and
the Subscription Agreements will be established by the Company following discussions and
arm’s-length negotiations with the Placement Agents and the Purchasers, and the Company is capable
of evaluating and understanding and understands and accepts the terms, risks and conditions of the
transactions contemplated by this Agreement;

          (c) Absence of Obligation to Disclose. The Company has been advised that the Placement Agents
and their affiliates are engaged in a broad range of transactions which may involve interests that
differ from those of the Company and that the Placement Agents have no obligation to disclose such
interests and transactions to the Company by virtue of any fiduciary, advisory or agency
relationship; and

          (d) Waiver. The Company waives, to the fullest extent permitted by law, any claims it may have
against the Placement Agents for breach of fiduciary duty or alleged breach of fiduciary duty and
agrees that the Placement Agents shall have no liability (whether direct or indirect) to the
Company in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim
on behalf of or in right of the Company, including stockholders, employees or creditors of the
Company.

15. Applicable Law. This Agreement shall be governed by, and construed in accordance with, the laws
of the State of New York.

          The Company hereby submits to the non-exclusive jurisdiction of the Federal and state courts
in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or
relating to this Agreement or the transactions contemplated thereby. The Company irrevocably and
unconditionally waives any objection to the laying of venue of any suit or proceeding arising out
of or relating to this Agreement or the transactions contemplated thereby in Federal and state
courts in the Borough of Manhattan in The City of New York and irrevocably and unconditionally
waives and agrees not to plead or claim in any such court that any such suit or proceeding in any
such court has been brought in an inconvenient forum.

[The remainder of this page is intentionally left blank]

- 14 -

 

          If the foregoing is in accordance with the Placement Agents’ understanding of our agreement,
kindly sign and return to the Company one of the counterparts hereof, whereupon it will become a
binding agreement between the Company and the Placement Agents in accordance with its terms.

	 	 	 	 	 	 	 
	 	 	Very truly yours,
	 
	 	 	 	 	 	 
	 	 	POLYMEDIX, INC.
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 

Signature Page to Placement Agency Agreement

- 15 -

 

          The foregoing Placement Agency Agreement is hereby confirmed and accepted as of the date first
above written.

	 	 	 	 	 	 	 
	 	 	Needham & Company LLC
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	Title:	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	WBB Securities, LLC
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	Title:	 	 	 	 

Signature Page to Placement Agency Agreement

- 16 -

 

SCHEDULE A

	1.	 	Statutory Prospectus Included in the General Disclosure Package

	 
	2	 	General Use Issuer Free Writing Prospectuses (included in the General Disclosure Package)

	 
	3.	 	Other Information Included in the General Disclosure Package

Section
4(f) Subsidiaries

	 	•	 	PolyMedix Pharmaceuticals, Inc.

Section 4(gg) Business of Subsidiaries

	 	•	 	For state tax purposes all assets, liabilities and operations are run at the subsidiary level;
the Company is the sole owner of the Company Subsidiary. For financial statement
purposes, the assets, liabilities and operations are consolidated with the parent company.

Section 4(hh) NASD Affiliations

	 	•	 	I. Wistar Morris and William Baquet, each deemed to be the beneficial owners of 4.9 and
over 5% of the Company’s common stock, respectively are members of the NASD. To
the Company’s knowledge, neither Mr. Morris or Mr. Baquet have acquired securities of
the Company within 180 days of the filing of the Registration Statement.

	4.	 	Permitted Free Writing Prospectus

- 17 -

 

SCHEDULE B

Information provided by the Placement Agents for inclusion in the Registration Statement

	1.	 	The Needham and WBB names and logos, as well as style instructions for the Prospectus.

	 
	2.	 	Cover page to the Prospectus relating to Needham, WBB and the Placement Agents and the
manner of selling efforts set forth on the Cover Page.

	 
	3.	 	Prospectus Summary information relating to the offering of the Units.

	 
	4.	 	The section of the Prospectus entitled “Plan of Distribution”.

- 18 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]